Method of administration of IGF-I

Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai

Patent

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

514 2, 514 21, A61K 3800, A61K 3827

Patent

active

055654282

ABSTRACT:
A method is disclosed that comprises administering insulin-like growth factor-I (IGF-I) to a mammal so as to sustain its biological activity in the mammal comprising administering a therapeutically effective amount of IGF-I to the mammal to provide an exposure to IGF-I for a period of time that stimulates the maximum biological response in the mammal, then discontinuing said administration for a period of time equal to or less than the time period used for administration, and repeating this pattern of administration and discontinuance of administration for a period as long as necessary to achieve or maintain the desired biological response in the mammal.

REFERENCES:
patent: 4876242 (1989-10-01), Applebaum
patent: 4988675 (1991-01-01), Froesch et al.
patent: 5068224 (1991-11-01), Fryklund et al.
patent: 5093317 (1992-03-01), Lewis et al.
patent: 5106832 (1992-04-01), Froesch et al.
patent: 5126324 (1992-06-01), Clark et al.
patent: 5187151 (1993-02-01), Clark et al.
patent: 5202119 (1993-04-01), Clark et al.
patent: 5273961 (1993-12-01), Clark
patent: 5374620 (1994-12-01), Clark et al.
Baxter, "The somatomedins: insulin-like growth factors" Advances in Clinical Chemistry 25:49-115 (1986).
Binoux, M., "Donnees recentes sur les somatomedines" Annales d'Endocrinologie 41:157-191 (1980).
Chen et al., "Recombinant human IGF-I infusion results in transient improvement in nitrogen balance: evidence for IGF-I autoregulation" US Endocrine Meeting (Abstract 1596) p. 449 (1993).
Clemmons and Van Wyk, "Somatomedin: physiological control and effects on cell proliferation" Handbook Exp. Pharmacol. 57:161-208 (1981).
Cohick and Clemmons, "The insulin-like growth factors" Annu. Rev. Physiol. 55:131-153 (1993).
Duerr et al., "Insulin-like growth factor-1 enhances ventricular hypertrophy and function during the onset of experimental cardiac failure" J. Clin. Invest. 95:619-627 (1995).
Elahi et al., "Hemodynamic and metabolic responses to human insulin-like growth factor I (IGF-I) in men" Modrn Concepts of Insulin-Like Growth Factors, Spenser, ed., New York:Elsevier Science Publ. Co. pp. 219-224 (1991).
Guler et al., "Effects of recombinant insulin-like growth factor I on insulin secretion and renal function in normal human subjects" Proc. Natl. Acad. Sci. USA 86:2868-2872 (Apr. 1989).
Guler et al., "Insulin-like growth factor I increases glomerular filtration rate and renal plasma flow in man" Acta Endocrinologica 121:101-106 (1989).
Guler et al., "Recombinant human insulin-like growth factor 1 stimulates growth and has distinct effects on organ size in hypophysectomized rats" Proc. Natl. Acad. Sci. USA 85:4889-4893 (1988).
Guler et al., "Short-term metabolic effects of recombinant human insulin-like growth factor I in healthy adults" New England J. of Medicine 317(3):137-140 (1987).
Hammerman, "Ask the expert: What are the clinical uses of IGF I in acute and chronic renal failure?" Ped. Nephrology 8:544 (1994).
Hammerman and Miller, "The growth hormone insulin-like factor axis in kidney revisited" Am. J. Physiol. 265:F1-F14 (1993).
Hammerman and Miller, "Therapeutic use of growth factors in renal failure" J. Am. Soc. Nephrol. 5:1-11 (1994).
Hirschberg et al., "Effects of insulin-like growth factor I on renal function in normal men" Kidney International 43:387-397 (1993).
Hise et al., "Influence of circulating insulin-like growth factor-I compared with that of intrarenal insulin-like growth factor-I on proximal nephron receptor density in rats" Clinical Science 83:233-239 (1992).
Hoogenberg et al., "Effect of growth hormone and insulin-like growth factor I on urinary albumin excretion: studies in acromegaly and growth hormone deficiency" Acta Endocrinologica 129:151-157 (1993).
Ikkos et al., "Glomerular filtration rate and renal plasma flow in acromegaly" Acta Endocrinologica 21:226-236 (1956).
Jabri et al., "Adverse effects of recombinant human insulin-like growth factor I in obese insulin-resistant type II diabetic patients" Diabetes 43:369-374 (1994).
Kanety et al., "Long-term treatment of Laron type dwarfs with insulin-like growth factor-1 increases serum insulin-like growth factor-binding protein-3 in the absence of growth hormone activity" Acta Endocrinologica 128:144-149 (1993).
Kerr et al., "Effect of insulin-like growth factor-1 on the responses to and recognition of hypoglycemia in humans" J. Clin. Invest. 91:141-147 (1993).
Kupfer et al., "Enhancement of the anabolic effects of growth hormone and insulin-like growth factor I by use of both agents simultaneously" J. Clin Invest. 91:391-396 (1993).
Lieberman et al., "Anabolic effects of recombinant insulin-like growth factor I in AIDS-associated cachexia" US Endocrine Meeting (Abstract 1664) p. 466 (1993).
Lieberman et al., "Anabolic effects of recombinant insulin-like growth factor-I in cachectic patients with the acquired immunodeficiency syndrome" J. Clin. Endocrinol. and Metab. 78(2):404-410 (1994).
Lieberman et al., "Effects of recombinant human insulin-like growth factor-I (rhIGF-I) on total and free IGF-I concentrations, IGF-binding proteins, and glycemic response in humans" J. Clin. Endocrinol. and Metab. 75(1):30-36 (1992).
Miller et al., "Effects of IGF-I on reneal function in end-stage chronic renal failure" Kidney Int. 46:201-207 (1994).
O'Shea and Layish, "Growth hormone and the kidney: a case presentation and review of the literature" J. Am. Soc. Nephrol. 3:157-161 (1992).
O'Shea et al., "Effects of IGF-I on renal function in patients with chronic renal failure" Am. J. Physiol. 264:F917-F922 (1993).
O'Shea et al., "Roles of growth hormone and growth factors in the pathogenesis and treatment of kidney disease" Current Opinion in Neph. and Hypertension 2:67-72 (1993).
Quigley and Baum, "Effects of growth hormone and insulin-like growth factor I on rabbit proximal convoluted tubule transport" J. Clin. Invest. 88:368-374 (1991).
Quin et al. New England J. of Medicine 323:1425-1426 (1990).
Rinderknecht and Humbel, "The amino acid sequence of human insulin-like growth factor I and its structural homology with proinsulin" Journal of Biological Chemistry 253(8):2769-2776 (1978).
Rinderknecht and Humbel, "Polypeptides with nonsuppressible insulin-like and cell-growth promoting activities in human serum: isolation, chemical characterization, and some biological properties of forms I and II" Proc. Natl. Acad. Sci USA 73(7):2365-2369 (1976).
Schalch et al., "Short-term metabolic effects of recombinant human insulin-like growth factor I (rhIGF-I) in type II diabetes mellitus" Modern Concepts of Insulin-Like Growth Factors, Spencer, ed., New York:Elsevier Science Publ. Co. pp. 705-714 (1991).
Schoenle et al., "Recombinant human insulin-like growth factor I(rhIGF-I) reduces hyperglycaemia in patients with extreme insulin resistance" Diabetologia 34:675-679 (1991).
Underwood et al., "Regulation of somatomedin-c/insulin-like growth factor I by nutrients" Hormone Res. 24:166-176 (1986).
Usala et al., "Brief report: treatment of insulin-resistant diabetic ketoacidosis with insulin-like growth factor I in an adolescent with insulin-dependent diabetes" New England J. of Medicine 327(12):853-857 (1992).
Van Wyk et al., "The somatomedins: a family of insulinlike hormones under growth hormone control" Recent Prog. Horm. Res. 30:259-318 (1974).
Walker et al., "Stimulation of statural growth by recombinant insulin-like growth factor I in a child with growth hormone insensitivity syndrome (Laron type)" J. Pediatr. 121:641-646 (1992).
Wilton et al., "Treatment with recombinant human insulin-like growth factor I of children with growth hormone receptor deficiency (Laron syndrome)" Acta Paediatr Suppl 383:137-141 (1992).
Zenobi et al., "Effects of insulin-like growth factor-I on glucose tolerance, insulin levels, and insulin secretion" J. Clin. Invest. 89:1908-1913 (1992).
Zenobi et al., "Insulin-like growth factor-I improves glucose lipid metabolism in type 2 diabetes mellitus" J. Clin. Invest. 90:2234-2241 (1992).

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

Method of administration of IGF-I does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Method of administration of IGF-I, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of administration of IGF-I will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-1246106

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.